Quick Answer
ALNYLAM PHARMACEUTICALS, INC. reported Net Income of $313.75 million for fiscal year 2025.
ALNYLAM PHARMACEUTICALS, INC. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | $313.75M | +212.8% |
| 2024 | -$278.16M | +36.8% |
| 2023 | -$440.24M | +61.1% |
| 2022 | -$1.13B | -32.6% |
| 2021 | -$852.82M | +0.6% |
| 2020 | -$858.28M | +3.1% |
| 2019 | -$886.12M | -16.4% |
| 2018 | -$761.50M | -55.1% |
| 2017 | -$490.87M | -19.7% |
| 2016 | -$410.11M | -41.4% |
| 2015 | -$290.07M | +19.5% |
| 2014 | -$360.39M | -303.9% |
| 2013 | -$89.22M | +15.8% |
| 2012 | -$106.01M | -83.9% |
| 2011 | -$57.65M | -32.5% |
| 2010 | -$43.52M | +8.6% |
| 2009 | -$47.59M | -81.3% |
| 2008 | -$26.25M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $251.08M | +325.0% | +478.8% |
| June 30, 2025 | -$66.28M | -292.4% | -15.3% |
| March 31, 2025 | -$57.48M | +12.8% | +48.5% |
| September 30, 2024 | -$111.57M | -175.5% | -560.6% |
| June 30, 2024 | -$16.89M | +93.9% | +74.4% |
| March 31, 2024 | -$65.94M | +62.1% | -144.6% |
| September 30, 2023 | $147.75M | +136.4% | +153.5% |
| June 30, 2023 | -$276.02M | +0.5% | -58.5% |
- ALNYLAM PHARMACEUTICALS, INC. showed an increase of +212.8% in Net Income compared to the prior fiscal year.
- Over the 2008–2025 period, ALNYLAM PHARMACEUTICALS, INC.’s net income has grown by 1295.3% (from -$26.25 million to $313.75 million).
- The most recent figure is from ALNYLAM PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: